A Study of Pyrimethamine in the Treatment of Infection by a Certain Parasite in HIV-Positive Patients
Completed · Phase 1
Conditions studied: Toxoplasmosis, Cerebral, HIV Infections
In brief
To determine the manner in which pyrimethamine is metabolized and excreted in patients currently receiving zidovudine (AZT). An important goal of this measurement is to establish the optimal dose of pyrimethamine necessary to prevent the development of toxoplasmosis in AIDS patients or delay the subsequent return of toxoplasmic encephalitis. Encephalitis caused by Toxoplasma gondii has emerged as the most frequent cause of focal central nervous system infection in patients with AIDS. Untreated, the encephalitis is fatal. The best treatment for this disease has not been determined. Presently it is standard practice to administer a combination of pyrimethamine and sulfadiazine. Little is known about the pharmacokinetics of pyrimethamine in patients with AIDS receiving AZT. Furthermore, there are reports that patients already exposed to toxoplasmosis may not have uniform absorption of pyrimethamine.
Key facts
- Study ID
- NCT00000973
- Run by
- National Institute of Allergy and Infectious Diseases (NIAID)
- People needed
- 26
- Expected to finish
- 1995-03-01
- Last updated by the study team
- 2021-11-04
Who can join
Age: 18 and older. Sex: any. Healthy volunteers: not accepted.
You may qualify if…
- Concurrent Medication:
- Allowed:
- Aerosolized pentamidine for Pneumocystis carinii pneumonia prophylaxis.
- Isoniazid not initiated during study period.
- Methadone maintenance.
- Required:
- Stable prescribed dose of zidovudine (AZT) of at least 500 mg/day.
You may not qualify if…
- Co-existing Condition:
- Patients with the following conditions or symptoms are excluded:
- Prior history of toxoplasmic encephalitis.
- Unable to take oral medication reliably or have a malabsorption syndrome (i.e., 3 or more loose stools/day for at least 4 weeks associated with an unintentional weight loss of = or > 10 percent of body weight).
- History of sensitivity to the study medications.
- Concurrent Medication:
- Excluded:
- Maintenance therapy for opportunistic infections with macrolides or sulfonamides, immunomodulators, rifampin, amphotericin, dapsone, ganciclovir, antifolates, probenecid, benzodiazepines, nephrotoxins, and experimental cytotoxic chemotherapy.
- Medications such as aspirin, benzodiazepines, cimetidine, indomethacin, morphine, and sulfonamides should be avoided.
- Concurrent Treatment:
- Excluded:
- Lymphocyte replacement.
- Patients with the following are excluded:
- Any medical or social condition that, in the opinion of the investigator, would adversely affect either participation or compliance in the study.
- Diagnosis of AIDS and febrile and have evidence of another serious opportunistic infection or central nervous system impairment.
- Prior Medication:
- Excluded:
- Maintenance therapy for opportunistic infections with macrolides or sulfonamides, immunomodulators, rifampin, amphotericin, dapsone, ganciclovir, antifolates, probenecid, benzodiazepines, nephrotoxins, and experimental cytotoxic chemotherapy within past 14 days.
- Prior Treatment:
- Excluded:
- Lymphocyte replacement within past 14 days.
- Patients have the following symptoms and conditions:
- Laboratory evidence of HIV infection.
- Serological evidence of exposure to Toxoplasma gondii, but no clinical evidence of active toxoplasmic infection.
- Able to understand and sign a written informed consent.
Where it is running
- Memorial Sloan-Kettering Cancer Ctr. — New York, New York, United States
- Unc Aids Crs — Chapel Hill, North Carolina, United States
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.